Back to videosWhile we wait for public orthopedic companies to announce 2025 first quarter results, we take a look at how the market finished in 2024, resurgent M&A volume early in the year and the potential impact of tariffs on the orthopedic industry. Mike Evers is an analyst and writer with over 15 years of...
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
